Bellvitge University Hospital

• Impact of Intraoperative Arteriography with Indocyanine Green in Preserving the Parathyroid Glands During Total Thyroidectomy With or Withou… Pending
  2023-509130-18-00 Phase III 1 country
• STUDY TO FIND OUT WHETHER A SHORTER ANTIBIOTIC TREATMENT (7 DAYS) IS AS EFFECTIVE AND SAFE AS THE USUAL ONE (14 DAYS) IN PATIENTS WITH AN IN… Pending
  2025-523120-53-00 Phase III/IV 1 country
• Efficacy and tolerability of efgartigimod as early treatment in patients with generalized myasthenia gravis. Recruiting
  2024-516015-24-00 Phase IV 1 country EFGARTIGIMOD ALFA
• GLP-1 receptor agonists as preventive treatment of diabetes after renal transplantation: randomized clinical trial. Study 1: Immediate Kidne… Recruiting
  2023-506437-29-00 Phase III 1 country DULAGLUTIDE
• A Non-Randomized, Open-Label Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive … Recruiting
  2024-515228-36-00 Phase IV 1 country HUMAN PAPILLOMAVIRUS TYPE 31 L1 PROTEIN - ADSORBED - IN THE FORM OF VIRUS-LIKE P…
• OPEN-LABEL EXTENSION STUDY TO ASSESS THE SAFETY AND LONG-TERM EFFECTIVENESS OF ORALLY ADMINISTERED EFAVIRENZ IN PATIENTS DIAGNOSED WITH ADUL… Ended
  2023-505832-36-01 Phase II 1 country
• VALSARTAN TREATMENT COMPARED IN RENAL TRANSPLANT RECIPIENTS WITH SIGNS OF POST TRANSPLANT GLOMERULOPATHY Ended
  2024-518723-30-01 Phase IV 1 country VALSARTAN
• Comparison of three short rifamycin-based regimens to treat latent tuberculosis in patients with end-stage kidney disease. Ended
  2023-506432-32-00 Phase IV 1 country ISONIAZID, PYRIDOXINE; RIFAMPICIN
• GLP-1 receptor agonists as preventive treatment of diabetes after renal transplantation: a single-arm interventional clinical trial. Study 2… Ended
  2023-506436-33-00 Phase III 1 country DULAGLUTIDE

Showing 1–9 of 9 trials